Characterization of the anxiolytic and sedative profile of JM-20: A novel benzodiazepine-dihydropyridine hybrid molecule

Neurological Research

Volumn 35, Issue 8, 2013, Pages 804-812

  Figueredo, Yanier Nuñez ^a   Rodríguez, Estael Ochoa ^b   Reyes, Yamila Verdecia ^b   Domínguez, Carmen Carrillo ^a   Parra, Alicia Lagarto ^a   Sánchez, Jeney Ramirez ^a   Hernández, René Delgado ^a   Verdecia, Marlene Porto ^a   Andreu, Gilberto L Pardo ^c  

^a CENTRO DE INVESTIGACIÓN Y DESARROLLO DE MEDICAMENTOS CIDEM   (Cuba)

^b UNIVERSITY OF HAVANA   (Cuba)

^c INSTITUTO DE FARMACIA Y ALIMENTOS   (Cuba)

Author keywords

Benzodiazepine derivative; GABA; JM 20; Neuroprotective; Sedative effects

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; BENZODIAZEPINE DERIVATIVE; DIAZEPAM; HALOPERIDOL; JM 20; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; AGGRESSION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICONVULSANT ACTIVITY; ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; CONTROLLED STUDY; DRUG SYNTHESIS; FEMALE; LATENT PERIOD; MALE; MAZE TEST; MOUSE; NONHUMAN; OPEN FIELD TEST; PROTON NUCLEAR MAGNETIC RESONANCE; RAT; SEDATION; SLEEP TIME; TONIC CLONIC SEIZURE; TOXICITY TESTING; TRANQUILIZING ACTIVITY;

ADMINISTRATION, ORAL; ANIMALS; ANTI-ANXIETY AGENTS; ANTICONVULSANTS; BEHAVIOR, ANIMAL; BENZODIAZEPINES; DIAZEPAM; DIHYDROPYRIDINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; DRUG INTERACTIONS; FEMALE; HYPNOTICS AND SEDATIVES; MALE; MICE; NIACIN; RATS;

EID: 84884180120     PISSN: 01616412     EISSN: 17431328     Source Type: Journal    
DOI: 10.1179/1743132813Y.0000000216     Document Type: Article

References (61)

1. Yang Y, Shuaib A, Li Q, Siddiqui MM. Neuroprotection by delayed administration of topiramate in a rat model of middle cerebral artery embolization. Brain Res. 1998;804:169-76.
2. Schwartz-Bloom RD, Sah R. Gamma-Aminobutyric acid(A) neurotransmission and cerebral ischemia. J Neurochem. 2001;77:353-71.
3. Leist M, Nicotera P. Apoptosis, excitotoxicity, and neuropathology. Exp Cell Res. 1998;239:183-201.
4. Ludolph AC, Meyer T, Riepe MW. The role of excitotoxicity in ALS what is the evidence? J Neurol. 2000;247:I7-16.
5. Cavalli A, Bolognesi ML, Minarini A, Rosini M, Tumiatti V, Recanatini M, et al. Multi-target-directed ligands to combat neurodegenerative diseases. J Med Chem. 2008;51:347-72.
6. Minnerup J, Schäbitz WR. Multifunctional actions of approved and candidate stroke drugs. Neurotherapeutics. 2009;6:43-52.
7. Corbett D, Larsen J, Langdon KD. Diazepam delays the death of hippocampal CA1 neurons following global ischemia. Exp Neurol. 2008;214:309-14.
8. Green AR, Hainsworth AH, Jackson DM. GABA potentiation: a logical pharmacological approach for the treatment of acute ischaemic stroke. Neuropharmacology. 2000;39:1483-94.
9. Iwata M, Inoue S, Kawaguchi M, Furuya H. Effects of diazepam and flumazenil on forebrain ischaemia in a rat model of benzodiazepine tolerance. Br J Anaesth. 2012;109:935-42.
10. Sarnowska A, Berȩsewicz M, Zablocka B, Domanska-Janik K. Diazepam neuroprotection in excitotoxic and oxidative stress involves a mitochondrial mechanism additional to the GABAAR and hypothermic effects. Neurochem Int. 2009; 55:164-73.
11. Babu CS, Ramanathan M. Post-ischemic administration of nimodipine following focal cerebral ischemic-reperfusion injury in rats alleviated excitotoxicity, neurobehavioural alterations and partially the bioenergetics. Int J Dev Neurosci. 2011;29:93-105.
12. Korenkov AI, Pahnke J, Frei K, Warzok R, Schroeder HWS, Frick R, et al. Treatment with nimodipine or mannitol reduces programmed cell death and infarct size following focal cerebral ischemia. Neurosurg Rev. 2000;23:145-50.
13. Zapater P, Moreno J, Horga JF. Neuroprotection by the novel calcium antagonist pca50938, nimodipine and flunarizine, in gerbil global brain ischemia. Brain Res. 1997;772:57-62.
14. Van der Schyf CJ. The use of multi-target drugs in the treatment of neurodegenerative diseases. Expert Rev Clin Pharmacol. 2011;4:293-98.
15. Dirnagl U, Simon RP, Hallenbeck JM. Ischemic tolerance and endogenous neuroprotection. Trends Neurosci. 2003;26:248-54.
16. Schwartz-Bloom RD, Miller KA, Evenson DA, Crain BJ, Nadler JV. Benzodiazepines protect hippocampal neurons from degeneration after transient cerebral ischemia: an ultrastructural study. Neuroscience. 2000;98:471-84.
17. Alba Guitiérrez LL, Carillo Domínguez C, Nuñez Figueredo Y, Ochoa Rodriguez E, Pardo Andreu GL, Ruiz Reyes A, et al. Tricyclic and tetracyclic system with activity on the central nervous and vascular systems. Publication No. EP2487174 A2 CU Patent 2009-0172. Available at: http://www.google.com/patents/EP2487174A2?cl5en (accessed 11 April 2013).
18. Archer J. Tests for emotionality in rats and mice: a review. Anim Behav. 1973;21:205-35.
19. Walsh RN, Cummins RA. The open-field test: a critical review. Psychol Bull. 1976;83:482-504.
20. Pinna G, Dong E, Matsumoto K, Costa E, Guidotti A. In socially isolated mice, the reversal of brain allopregnanolone down-regulation mediates the anti-aggressive action of fluoxetine. Proc Natl Acad Sci USA. 2003;100:2035-40.
21. Loscher W, Schmidt D. Which animal models should be used in the search for new antiepileptic drugs? A proposal based on experimental and clinical considerations. Epilepsy Res. 1988;2:145-81.
22. Chauhan K, Sheth N, Ranpariya V, Parmar S. Anticonvulsant activity of solasodine isolated from Solanum sisymbriifolium fruits in rodents. Pharm Biol. 2011;49:194-9.
23. Dawson GR, Tricklebank MD. Use of the elevated plus-maze in the search for novel anxiolytic agents. Trends Pharmacol Sci. 1995;16:33-6.
24. Moreira ELG, Rial D, Duarte FS, De Carvalho CR, Horst H, Pizzolatti MG, et al. Central nervous system activity of the proanthocyanidin-rich fraction obtained from Croton celtidifolius in rats. J Pharm Pharmacol. 2010;62:1061-8.
25. Ellinwood Jr EH, Balster RL. Rating the behavioral effects of amphetamine. Eur J Pharmacol. 1974;28:35-41.
26. OECD. Guideline for testing of chemicals. 423 Acute Oral Toxicity Acute Toxic Class Method. 2001.
27. Rex A, Voigt JP, Voits M, Fink H. Pharmacological evaluation of a modified open-field test sensitive to anxiolytic drugs. Pharmacol Biochem Behav. 1998;59:677-83.
28. Eloqayli H, Qu H, Unsgard G, Sletvold O, Hadidi H, Sonnewald U. Effects of pentylenetetrazole and glutamate on metabolism of [U-(13)C]glucose in cultured cerebellar granule neurons. Neurochem Int. 2002;40:181-7.
29. Pittson S, Himmel A, MacIver M. Multiple synaptic and membrane sites of anesthetic action in the ca1 region of rat hippocampal slices. BMC Neurosci. 2004;5:1-10.
30. Tanelian DL, Kosek P, Mody I, Maclver MB. The role of the GABAA receptor/chloride channel complex in anesthesia. Anesthesiology. 1993;78:757-76.
31. Lin HQ, Burden PM, Johnston GAR. Neuropharmacology: Propylene glycol elicits anxiolytic-like responses to the elevated plus-maze in male mice. J Pharm Pharmacol. 1998;50:1127-31.
32. Robl JA, Cimarusti MP, Simpkins LM, Brown B, Ryono DE, Bird JE, et al. Dual metalloprotease inhibitors. 6. Incorporation of bicyclic and substituted monocyclic azepinones as dipeptide surrogates in angiotensin-converting enzyme/neutral endopeptidase inhibitors. J Med Chem. 1996;39:494-502.
33. Vinkers CH, Olivier B. Mechanisms underlying tolerance after long-term benzodiazepine use: a future for subtype-selective GABAA receptor modulators? Adv Pharmacol Sci. 2012; 2012:19.
34. Wilson SC, Howard PW, Forrow SM, Hartley JA, Adams LJ, Jenkins TC, et al. Design, synthesis, and evaluation of a novel sequence-selective epoxide-containing DNA cross-linking agent based on the pyrrolo[2,1-c][1,4]benzodiazepine system. J Med Chem. 1999;42:4028-41.
35. Wyatt PG, Allen MJ, Chilcott J, Hickin G, Miller ND, Woollard PM. Structure-activity relationship investigations of a potent and selective benzodiazepine oxytocin antagonist. Bioorg Med Chem Lett. 2001;11:1301-5.
36. Sherrill RG, Berman JM, Birkemo L, Croom DK, Dezube M, Ervin GN, et al. 1,4-benzodiazepine peripheral cholecystokinin (CCK-A) receptor agonists. Bioorg Med Chem Lett. 2001;11:1145-8.
37. Prut L, Belzung C. The open-field as a paradigm to measure the effects of drugs on anxiety-like behaviors: a review. Eur J Pharmacol. 2003;463:3-33.
38. Crawley JN. Neuropharmacologic specificity of a simple animal model for the behavioral actions of benzodiazepines. Pharmacol Biochem Behav. 1981;15:695-9.
39. Rex A, Stephens DN, Fink H. 'Anxiolytic' action of diazepam and abecarnil in a modified open-field test. Pharmacol Biochem Behav. 1996;53:1005-11.
40. Gourley SL, DeBold JF, Yin W, Cook J, Miczek KA. Benzodiazepines and heightened aggressive behavior in rats: reduction by GABA(A)/alpha(1) receptor antagonists. Psychopharmacology. 2005;178:232-40.
41. Matsumoto K, Puia G, Dong E, Pinna G. GABA(A) receptor neurotransmission dysfunction in a mouse model of social isolation-induced stress: possible insights into a non-serotonergic mechanism of action of SSRIs in mood and anxiety disorders. Stress. 2007;10:3-12.
42. Bond AJ. Drug-induced behavioural disinhibition: incidence, mechanisms and therapeutic implications. CNS Drugs. 1998;9:41-57.
43. Ferrari PF, Parmigiani S, Rodgers RJ, Palanza P. Differential effects of chlordiazepoxide on aggressive behavior in male mice: the influence of social factors. Psychopharmacology. 1997; 134:258-65.
44. Liao Y-J, Zhai H-F, Zhang B, Duan T-X, Huang J-M. Anxiolytic and sedative effects of dehydroeffusol from Juncus effusus in mice. Planta Med. 2011;77:416-20.
45. Leeb-Lundberg F, Snowman A, Olsen RW. Barbiturate receptor sites are coupled to benzodiazepine receptors. Proc Natl Acad Sci USA. 1980;77:7468-72.
46. Asano T, Ogasawara N. Stimulation of GABA receptor binding by barbiturates. Eur J Pharmacol. 1982;77:355-7.
47. Schroder H, Becker A, Lossner B. Glutamate binding to brain membranes is increased in pentylenetetrazole-kindled rats. J Neurochem. 1993;60:1007-11.
48. Walsh LA, Li M, Zhao T-J, Chiu TH, Rosenberg HC. Acute pentylenetetrazol injection reduces rat GABAA receptor mRNA levels and GABA stimulation of benzodiazepine binding with no effect on benzodiazepine binding site density. J Pharmacol Exp Ther. 1999;289:1626-33.
49. Getova D, Froestl W, Bowery NG. Effects of GABAB receptor antagonism on the development of pentylenetetrazol-induced kindling in mice. Brain Res. 1998;809:182-8.
50. Rogawski MA, Porter RJ. Antiepileptic drugs: pharmacological mechanisms and clinical efficacy with consideration of promising developmental stage compounds. Pharmacol Rev. 1990;42:223-86.
51. Macdonald RL, Kelly KM. Antiepileptic drug mechanisms of action. Epilepsia. 1995;36:S2-12.
52. Rodger C, Pleuvry BJ. Protective effect of flunarizine and nifedipine alone and in combination with anticonvulsant drugs against PTZ-induced seizures in mice. Neuropharmacology. 1993;32:257-63.
53. Navidpour L, Shafaroodi H, Miri R, Dehpour AR, Shafiee A. Lipophilic 4-imidazoly-1,4-dihydropyridines: Synthesis, calcium channel antagonist activity and protection against pentylenetetrazole-induced seizure. Il Farmaco. 2004;59:261-9.
54. Pellow S, File SE. Anxiolytic and anxiogenic drug effects on exploratory activity in an elevated plus-maze: a novel test of anxiety in the rat. Pharmacol Biochem Behav. 1986;24:525-9.
55. Robinson TE, Becker JB. Enduring changes in brain and behavior produced by chronic amphetamine administration: a review and evaluation of animal models of amphetamine psychosis. Brain Res Rev. 1986;11:157-98.
56. Mehta VL, Malhotra CL. Anticonvulsant and some neuropharmacological properties of 2-methyl-3-o-tolyl-6-chloro-4(3H)-quinazolone and related compounds. J Pharm Pharmacol. 1966;18:536-9.
57. Sun T, Hu G, Li M. Repeated antipsychotic treatment progressively potentiates inhibition on phencyclidine-induced hyperlocomotion, but attenuates inhibition on amphetamineinduced hyperlocomotion: relevance to animal models of antipsychotic drugs. Eur J Pharmacol. 2009;602:334-42.
58. Dunne F, Halloran A, Kelly JP. Development of a home cage locomotor tracking system capable of detecting the stimulant and sedative properties of drugs in rats. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31:1456-63.
59. Chen JWY, Naylor DE, Wasterlain CG. Advances in the pathophysiology of status epilepticus. Acta Neurol Scand. 2007;115:7-15.
60. Letizia Trincavelli M, Da Pozzo E, Daniele S, Martini C. The GABAA-BZR complex as target for the development of anxiolytic drugs. Curr Top Med Chem. 2012;12:254-69.
61. Yin D-M, Chen Y-J, Sathyamurthy A, Xiong W-C, Mei L. Synaptic dysfunction in schizophrenia. In: Kreutz MR, Sala C (eds). Synaptic plasticity. Vienna: Springer; 2012. p. 493-516.